What is the recommended approach to aortic valve replacement, including criteria for surgical versus transcatheter replacement and postoperative antithrombotic therapy?

Aortic Valve Replacement: Approach and Management

Primary Recommendation

For patients with severe symptomatic aortic stenosis, transcatheter aortic valve replacement (TAVR) is recommended when anatomically suitable, regardless of surgical risk, with aspirin 75-100 mg daily lifelong plus clopidogrel 75 mg daily for 3-6 months as the standard post-procedural antithrombotic regimen. 1, 2

---

Criteria for Intervention

Symptomatic Severe Aortic Stenosis

• Any classic symptom attributable to severe AS (dyspnea, angina, syncope, heart failure) justifies valve replacement regardless of surgical risk when anatomy is suitable. 2
• Severe AS is defined as aortic valve area ≤1.0 cm² with peak velocity ≥4 m/s or mean gradient ≥40 mmHg. 2
• Very severe AS (peak velocity ≥5 m/s or mean gradient ≥60 mmHg) warrants earlier consideration for intervention. 2

Selected Asymptomatic Severe Aortic Stenosis

• Left ventricular ejection fraction <50% not due to another cause with peak velocity 4.0-4.9 m/s indicates intervention across all risk categories. 2
• Rapid disease progression (velocity increase >0.3 m/s/year), severe valve calcification, elevated natriuretic peptides, or marked LV hypertrophy without hypertension support offering valve replacement. 2
• Patients in high-risk professions (airline pilots, competitive athletes) or those away from medical supervision for prolonged periods may be considered even at low surgical risk. 2

---

TAVR vs. Surgical AVR Decision Framework

Heart Team Evaluation (Mandatory)

All valve replacement decisions require multidisciplinary Heart Team assessment including interventional cardiology, cardiac surgery, cardiac imaging specialists, anesthesiologists, and heart failure specialists. 1, 2, 3

Risk Stratification

• Low risk: STS-PROM <3% 2
• Intermediate risk: STS-PROM 4-8% 2
• High risk: STS-PROM ≥8% or ≥50% risk of mortality/irreversible morbidity at 30 days 3

Age-Based Considerations

• The European guidelines recommend surgical bioprosthesis threshold at ≥65 years, while American guidelines use multiple age categories allowing for patient factors and preferences. 1
• In patients ≤60 years, SAVR is associated with superior 5-year survival compared to TAVR (hazard ratio 2.5 for TAVR mortality), indicating SAVR should be strongly preferred in this age group. 4
• In Medicare beneficiaries aged 65-85 years with low and intermediate risk, SAVR demonstrates superior 5-year freedom from composite death, stroke, or valve reintervention (HR 0.85-0.86) compared to TAVR. 5

Anatomic Requirements for TAVR

• CT angiography of chest, abdomen, and pelvis with ECG-gated thoracic acquisition is required for pre-procedure anatomic evaluation. 3
• Key assessments include: iliofemoral vessel diameter with minimal calcification for transfemoral access, aortic annulus sizing, coronary ostia height, and aortic root calcification distribution. 3
• Predicted survival >12 months is required to justify TAVR intervention. 2, 3

Special Populations

• Bicuspid aortic valve patients have limited TAVR experience, though expanding; ascending aorta diameter >4.0 cm requires yearly imaging surveillance. 6
• LVEF <20% is a relative contraindication for TAVR but not absolute; LVEF 20-35% is acceptable for TAVR. 3
• Severe pulmonary hypertension contraindicates trans-apical TAVR but does not limit transfemoral TAVR; right-heart catheterization should be considered in TAVR candidates with PH. 3

---

Post-Procedural Antithrombotic Therapy

Standard Regimen (No Anticoagulation Indication)

Aspirin 75-100 mg daily lifelong plus clopidogrel 75 mg daily for 3-6 months is the guideline-recommended regimen after TAVR. 1

Evidence Considerations

• Moderate-strength evidence shows mortality, stroke, and major cardiac events are similar between dual antiplatelet therapy and aspirin alone after TAVR, with possibly lower bleeding with aspirin alone. 7
• Registry-based evidence suggests single antiplatelet therapy may be safer than dual antiplatelet therapy in patients without oral anticoagulation indication. 8

Patients Requiring Anticoagulation

• Warfarin (INR 2.0-2.5) should be considered if at risk of atrial fibrillation or venous thromboembolism. 1
• Oral anticoagulation monotherapy appears superior to anticoagulation plus antiplatelet therapy when oral anticoagulant use is indicated. 8
• Patients with chronic AF or other indications for long-term anticoagulation should receive anticoagulation as per guidelines for AF in patients with prosthetic heart valves. 1
• Continuation of aspirin with warfarin is reasonable, but avoid additional antiplatelet therapy given increased bleeding risk with multiple antithrombotic agents. 1

Alternative Considerations

• Vitamin K antagonist therapy may be considered in the first 3 months after TAVR in patients at risk of AF or valve thrombosis, depending on specific risk-benefit ratio. 1
• Small study data suggest patients on vitamin K antagonist therapy have lower rates of subclinical leaflet thrombus formation than those on antiplatelet therapy, though no randomized studies exist. 1

---

Post-Procedural Management and Monitoring

Immediate Post-Procedure (First 30 Days)

• The TAVR team maintains primary responsibility for care during the first 30 days when procedural complications are most likely. 1
• Early extubation is encouraged when general anesthesia is used. 1
• Monitor access site carefully for bleeding, hematoma, or pseudoaneurysm formation. 1
• Early mobilization with physical and occupational therapy assessment is essential, especially in elderly patients with high comorbidity burden. 1
• Early discharge within 72 hours does not increase 30-day mortality, bleeding, pacemaker implantation, or rehospitalization in selected transfemoral TAVR patients. 1

Follow-Up Schedule

• First follow-up at 30 days with formal transfer of care from Heart Valve Team back to referring primary cardiologist. 1
• Stable patients with no complications: primary cardiologist sees patient at 6 months, then annually. 1
• Primary care provider appointment scheduled no later than 3 months post-procedure. 1
• More frequent follow-up needed for symptom changes or transient conduction abnormalities. 1

Surveillance Testing

• Echocardiography at 30 days then annually to assess valve function, paravalvular regurgitation, LV function, and pulmonary pressure. 1, 3
• ECG at 30 days and annually; consider 24-hour ECG if bradycardia present. 1
• Monitor laboratory results for blood counts, metabolic panel, and renal function. 1

Comorbidity Management

• Manage concurrent cardiac conditions including coronary disease, hypertension, heart failure, and arrhythmias (especially AF). 1
• Assess pulmonary, renal, GI, and neurological function by primary care provider annually or as needed. 1
• Readmission rates exceed 40% in the first year after TAVR, most often due to noncardiac causes (60%); common diagnoses include respiratory problems, infections, and bleeding events. 1

Endocarditis Prophylaxis

• Encourage optimal dental care. 1
• Antibiotic prophylaxis per AHA/ACC guidelines. 1

---

Key Complications and Outcomes

TAVR-Related Complications

• Mortality: 3-5% at 30 days 3
• Stroke: 6-7% (lower than surgical AVR in recent trials for intermediate/low-risk patients, but constant risk beginning at implant) 3, 8
• Vascular access complications: 17% 3
• Permanent pacemaker requirement: 2-43% (varies significantly by valve type and patient anatomy) 3, 9
• Transient ischemic attack risk increased with TAVR (RR 1.43) 9
• Aortic valve reintervention risk increased at 1 year (RR 2.63) and 2 years (RR 3.19) compared to SAVR in low-to-intermediate risk patients 9

TAVR Advantages Over SAVR

• Lower risk of post-procedural bleeding (RR 0.57) 9
• Lower risk of new-onset or worsening atrial fibrillation (RR 0.32) 9
• Lower risk of acute kidney injury (RR 0.40) 9
• Lower risk of cardiogenic shock (RR 0.34) 9

---

Common Pitfalls to Avoid

• Do not proceed with TAVR if expected benefit is less than expected risk: futility indicators include multiple organ system failure, severe frailty, advanced cognitive impairment, life expectancy <12 months from non-cardiac causes, and patient goals incompatible with realistic procedural outcomes. 3
• Do not use dual antiplatelet therapy routinely without considering bleeding risk: current evidence suggests single antiplatelet therapy may be safer in patients without anticoagulation indication. 8, 7
• Do not combine anticoagulation with antiplatelet therapy routinely: oral anticoagulation monotherapy is superior when anticoagulation is indicated. 8
• Do not overlook age-specific outcomes: TAVR in patients ≤60 years shows significantly worse 5-year survival compared to SAVR, indicating need for careful patient selection. 4